论文部分内容阅读
目的:研究食管癌后程加速超分割放疗联合应用参芪扶正注射液增敏和降低放疗反应。方法:60例食管癌患者随机平均分成两组,一组行单纯后程加速超分割放疗(单放组),1次/天,2Gy/次,5次/周,总剂量达40Gy,20次后改为2次/天,1.5Gy/次,10次/周,总剂量64Gy。另一组在后程加速超分割放疗的同时加用参芪扶正注射液(综合组),参芪扶正注射液250ml静脉滴注,每日1次,连用28天。结果:放射治疗结束时食管片的分级综合治疗组1级占56.7%,明显高于单放组26.7%(P<0.05);综合组1年生存率80.0%,明显高于单放组43.3%(P<0.05);1级以上胃肠道反应综合组为6.7%,明显低于单放组30.0%(P<0.05);白细胞Ⅰ~Ⅱ级下降综合组占20.0%,明显低于单放组63.3%(P<0.05)。结论:食管癌后程加速超分割放疗联合应用参芪扶正注射液具有增敏和降低放疗反应作用。
OBJECTIVE: To study the late course of esophageal cancer accelerated hyperfractionation radiotherapy combined with Shenqi Fuzheng injection to enhance the sensitivity and reduce the radiotherapy response. Methods: Sixty patients with esophageal cancer were randomly divided into two groups. One group was treated with simple late-course hyperfractionated radiotherapy (single radiotherapy group, once daily, 2Gy / time, 5 times / week) After the change to 2 times / day, 1.5Gy / time, 10 times / week, the total dose of 64Gy. The other group in the latter part of accelerated hyperfractionation radiotherapy plus Shenqifuzheng injection (comprehensive group), Shenqi Fuzheng injection 250ml intravenous infusion once daily for 28 days. Results: At the end of radiotherapy, grade 1 of esophageal composite grading group was 56.7%, which was significantly higher than that of single group (26.7%, P <0.05). The 1-year survival rate was 80.0% in combination group, significantly higher than 43.3% (P <0.05). The level of gastrointestinal reaction group with grade 1 or above was 6.7%, which was significantly lower than that of group L with 30.0% (P <0.05). The grade Ⅰ ~ Ⅱ with leucocyte decreased 20.0% Group 63.3% (P <0.05). Conclusion: Accelerated hyperfraction esophageal cancer radiotherapy combined with Shenqi Fuzheng injection can sensitize and reduce the radiotherapy response.